1. Home
  2. AVDL vs RCUS Comparison

AVDL vs RCUS Comparison

Compare AVDL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • RCUS
  • Stock Information
  • Founded
  • AVDL 2015
  • RCUS 2015
  • Country
  • AVDL Ireland
  • RCUS United States
  • Employees
  • AVDL N/A
  • RCUS N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • RCUS Health Care
  • Exchange
  • AVDL Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • AVDL 784.6M
  • RCUS 727.1M
  • IPO Year
  • AVDL 1996
  • RCUS 2018
  • Fundamental
  • Price
  • AVDL $9.50
  • RCUS $8.40
  • Analyst Decision
  • AVDL Strong Buy
  • RCUS Buy
  • Analyst Count
  • AVDL 7
  • RCUS 11
  • Target Price
  • AVDL $18.86
  • RCUS $25.67
  • AVG Volume (30 Days)
  • AVDL 1.2M
  • RCUS 1.2M
  • Earning Date
  • AVDL 05-07-2025
  • RCUS 05-06-2025
  • Dividend Yield
  • AVDL N/A
  • RCUS N/A
  • EPS Growth
  • AVDL N/A
  • RCUS N/A
  • EPS
  • AVDL N/A
  • RCUS N/A
  • Revenue
  • AVDL $194,450,000.00
  • RCUS $141,000,000.00
  • Revenue This Year
  • AVDL $50.53
  • RCUS N/A
  • Revenue Next Year
  • AVDL $32.33
  • RCUS $25.77
  • P/E Ratio
  • AVDL N/A
  • RCUS N/A
  • Revenue Growth
  • AVDL 252.64
  • RCUS N/A
  • 52 Week Low
  • AVDL $6.38
  • RCUS $6.50
  • 52 Week High
  • AVDL $17.85
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 65.93
  • RCUS 53.47
  • Support Level
  • AVDL $8.55
  • RCUS $7.06
  • Resistance Level
  • AVDL $9.98
  • RCUS $9.35
  • Average True Range (ATR)
  • AVDL 0.50
  • RCUS 0.54
  • MACD
  • AVDL 0.11
  • RCUS 0.09
  • Stochastic Oscillator
  • AVDL 77.73
  • RCUS 72.05

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: